With the COVID-19 pandemic wreaking havoc in financial markets, investors want to buy shares of companies with solid underlying businesses that can survive or even profit from downturns -- especially those that have proven themselves before.With a sound core business, skyrocketing catalysts, and a healthy dividend, I believe Gilead is a great biotech stock to add to investors' portfolios.